These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 35698070)

  • 21. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
    Kwon S; Gil YE; Lee MJ
    Cephalalgia; 2022 Jul; 42(8):705-714. PubMed ID: 35301884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
    Tepper SJ; Ailani J; Ford JH; Nichols RM; Li LQ; Kemmer P; Hand AL; Tockhorn-Heidenreich A
    Clin Drug Investig; 2022 Mar; 42(3):263-275. PubMed ID: 35041159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis.
    Ailani J; Andrews JS; Tockhorn-Heidenreich A; Wenzel R; Rettiganti M
    Adv Ther; 2022 Oct; 39(10):4544-4555. PubMed ID: 35930126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.
    Lipton RB; Buse DC; Sandoe CH; Ford JH; Hand AL; Jedynak JP; Port MD; Detke HC
    Headache; 2023 May; 63(5):683-691. PubMed ID: 36797223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
    Smitherman TA; Tietjen GE; Schuh K; Skljarevski V; Lipsius S; D'Souza DN; Pearlman EM
    Headache; 2020 Nov; 60(10):2202-2219. PubMed ID: 33063862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2.
    MacGregor EA; Okonkwo R; Detke HC; Polavieja P; Fernandes MS; Pavlovic JM
    Headache; 2024 Feb; 64(2):179-187. PubMed ID: 38017629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies.
    Dell Agnello G; Buzzoni C; Antenori A; Torelli F; Altamura C; Vernieri F
    Clin Neuropharmacol; 2023 Nov-Dec 01; 46(6):220-228. PubMed ID: 37962309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).
    Tobin JA; Joshi S; Ford JH; Nichols RM; Foster SA; Ruff D; Detke HC; Aurora SK
    J Med Econ; 2022; 25(1):1030-1038. PubMed ID: 35971655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
    Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
    J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study.
    Lee HC; Cho S; Kim BK
    Neurol Sci; 2023 Jul; 44(7):2455-2463. PubMed ID: 36826456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry.
    Obach V; Velasco F; Alvarez Escudero R; Martín Bujanda M; Aranceta S; Fabregat N; Marco T; Ruisanchez A; Roncero N; Mínguez-Olaondo A; Ruibal M; Guisado-Alonso D; Moreira A; Cuadrado-Godia E; Echeverria A; Kortazar Zubizarreta I; López-Bravo A; Riesco N; González-Fernández L; Pola N; Manera P; Guerrero-Peral ÁL; Oterino Duran A; González-Osorio Y; Armand R; Fernández-Fernández S; García-Azorín D; García-Moncó JC
    J Headache Pain; 2023 Nov; 24(1):157. PubMed ID: 37993795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
    Ossipov MH; Raffa RB; Pergolizzi JV
    Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.
    Guerzoni S; Baraldi C; Castro FL; Cainazzo MM; Pani L
    Brain Behav; 2023 Jun; 13(6):e2799. PubMed ID: 37208838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
    Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
    Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.